En Carta
Biotechnology · Diagnostic Tests & IVD
Facts
as of Nov 22, 2026En Carta Diagnostics develops molecular tests, as easy to use as rapid tests, as precise as a PCR machine. We currently offer Lyme disease early detection kits and CT/NG - Chlamydia and Gonorrhea kits.
- Employees
- 11-50estimated range
- Website
- encarta.bio
These are the key facts about En Carta on Alion as of Nov 22, 2026. The latest round is Venture - Series Unknown of $6.2M, announced in 2026.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 1 record →En Carta has $6.2M paid in by investors, lenders and donors.
$6.2MPaid in
Money innewest first
$6.2MPaid
Money by yearUSD, rounds and grants
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Ownership
All holders and entities →Sources name Blue Forest Ventures among the owners or investors of En Carta.
Named investors, no share stated1
Blue Forest Ventures
Holders and shares as each register or filing states them.
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Jul 13
Each milestone is dated by its source: registers, filings, the press
